Treace Medical Concepts (TMCI) Expected to Announce Quarterly Earnings on Thursday

Treace Medical Concepts (NASDAQ:TMCI) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $61.7630 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

Treace Medical Concepts Price Performance

Treace Medical Concepts stock opened at $1.97 on Wednesday. The business’s fifty day moving average is $2.38 and its two-hundred day moving average is $4.49. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.36 and a current ratio of 3.37. The firm has a market cap of $125.52 million, a P/E ratio of -2.46 and a beta of 0.74. Treace Medical Concepts has a 52 week low of $1.81 and a 52 week high of $10.03.

Institutional Investors Weigh In On Treace Medical Concepts

Several institutional investors have recently modified their holdings of the business. Kotler Kevin acquired a new position in Treace Medical Concepts in the fourth quarter valued at approximately $1,162,000. Paradigm Capital Management Inc. NY bought a new stake in shares of Treace Medical Concepts during the 2nd quarter valued at $1,577,000. Millennium Management LLC raised its position in shares of Treace Medical Concepts by 12.7% during the 3rd quarter. Millennium Management LLC now owns 1,710,140 shares of the company’s stock valued at $11,475,000 after acquiring an additional 192,929 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Treace Medical Concepts in the 4th quarter valued at $380,000. Finally, Moore Capital Management LP acquired a new position in shares of Treace Medical Concepts in the 3rd quarter valued at $990,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TMCI shares. Stifel Nicolaus reduced their price target on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, January 7th. Truist Financial dropped their target price on shares of Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Wednesday, January 21st. BTIG Research reissued a “neutral” rating on shares of Treace Medical Concepts in a report on Friday, November 7th. Finally, Wall Street Zen upgraded shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Monday. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Treace Medical Concepts currently has a consensus rating of “Reduce” and an average price target of $4.21.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.